DRUG
ALT-801
Injected subcutaneously (SC)
Status
Completed
Phase
Phase 2
Enrollment
391
Locations
31
Results
Not posted
Publications
0
Study summary
This study will evaluate the efficacy and safety of ALT-801 once-weekly versus placebo as an adjunct to a reduced-calorie diet and increased physical activity in patients with obesity/overweight.
Interventions
DRUG
Injected subcutaneously (SC)
OTHER
Injected subcutaneously (SC)
Timeline
First posted
Mar 25, 2022
Study start
Mar 31, 2022
Primary completion
Sep 28, 2023
Study completion
Sep 28, 2023
Results posted
Not reported
Registry updated
Nov 29, 2023
Outcomes
Relative change from baseline in body weight percentage
Time frame · Baseline to Week 48
Percent proportion of subjects with weight loss of greater than or equal to 5%, 10%, and 15%
Time frame · Baseline to Week 48
Change from baseline in lipids
Time frame · Baseline to Week 48
The Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs)
Time frame · Baseline to Week 48
Changes from baseline in Fasting Glucose
Time frame · Baseline to Week 48
Changes from baseline in Hemoglobin A1c
Time frame · Baseline to Week 48
Changes from baseline in Homeostatic Marker Assessment for Insulin Resistance (HOMA-IR)
Time frame · Baseline to Week 48
Changes from baseline in: a) Systolic blood pressure, b) Diastolic blood pressure
Time frame · Baseline to Week 48
Change from baseline in proportion of patients using antihypertensive medications
Time frame · Baseline to Week 48
Eligibility
Inclusion Criteria: * Written informed consent signed prior to entry into the study * Male or female age 18 to 75 years, inclusive * Body mass index (BMI) ≥ 30 kg/m2 or BMI ≥ 27 kg/m2 combined with at least one obesity-related comorbidity * At least one unsuccessful weight loss attempt per investigator judgement * Agreement to comply with the study-required life-style intervention and treatment during the full duration of the study * Female subjects of childbearing potential who are not pregnant or breastfeeding, do not plan to become pregnant during the study, and agree to use effective birth control Exclusion Criteria: * Weight gain or loss \> 5% in the 3 months prior to randomization or \>10% in the 6 months prior to screening * Diabetes and related conditions: 1. History or clinical evidence of diabetes mellitus of any type, including Type 1, Type 2, or mature onset diabetes of the young (MODY) 2. HbA1c \> 6.5%, fasting glucose ≥ 126 mg/dL (6.9 mmol/L), and/or random glucose of ≥ 200 mg/dL (11.0mmol/L) at screening * Obesity and related conditions: 1. Obesity induced by known genetic causes or endocrine disorders (eg, Cushing Syndrome, inadequately treated hypothyroidism, defined as thyroid-stimulating hormone \[TSH\] \> 6 mIU/L) 2. History of bariatric surgery or other surgical treatment for obesity (eg, gastric banding, gastric bypass), or planned surgery or surgical treatment during the study. Liposuction and/or abdominoplasty performed \>1 year before screening is allowed. Endoscopically placed intragastric balloons will be allowed if removed \> 1 year before screening. * Gastrointestinal conditions: 1. History of acute or chronic pancreatitis within 1 year (365 days) before screening 2. History of or acute significant gastrointestinal (GI) disorder (eg, peptic ulcers, severe gastroesophageal reflux disease \[GERD\], 3. History of GI surgery, including cholecystectomy and antrectomy. Surgery for appendicitis and small bowel resection \>20cm is acceptable. 4. History of inflammatory bowel disease, celiac disease or any medical condition or surgery that could affect gastric emptying, stool frequency or stool consistency. (Irritable bowel syndrome is permitted provided that bowel frequency and consistency are normal off treatment.) * Mental health conditions: 1. Untreated depressive disorder, defined as a Patient Health Questionaire-9 (PHQ-9) score of ≥ 15 at screening 2. Suicide ideation, defined as type 4 or 5 on the Columbia-Suicide Severity Rating Scale(C-SSRS) at screening, lifelong history of a suicide attempt, or suicidal behavior within 30 days before screening 3. Other severe psychiatric disorder (eg, schizophrenia, bipolar disorder)
Study locations
United States. Showing up to 24 locations stored in the fast local snapshot.
Altimmune CTM
Birmingham, Alabama, United States
Altimmune CTM
Mesa, Arizona, United States
Altimmune CTM
Los Angeles, California, United States
National Research Institute
Los Angeles, California, United States
Altimmune CTM
Montclair, California, United States
Altimmune CTM
Santa Barbara, California, United States
Altimmune CTM
Boca Raton, Florida, United States
Altimmune CTM
Clearwater, Florida, United States
Altimmune CTM
Fort Myers, Florida, United States
Altimmune CTM
Jacksonville, Florida, United States
Altimmune CTM
Port Orange, Florida, United States
Altimmune CTM
Sunrise, Florida, United States
Altimmune CTM
Savannah, Georgia, United States
Altimmune CTM
Evanston, Illinois, United States
Altimmune CTM
Indianapolis, Indiana, United States
Midwest Institute for Clinical Research
Indianapolis, Indiana, United States
Altimmune CTM
Louisville, Kentucky, United States
Altimmune CTM
Baton Rouge, Louisiana, United States
Altimmune CTM
New Orleans, Louisiana, United States
Altimmune CTM
Kansas City, Missouri, United States
Altimmune CTM
Butte, Montana, United States
Altimmune CTM
Berlin, New Jersey, United States
Altimmune CTM
New York, New York, United States
Cornell University, Joan and Sanford Weill Medical College
New York, New York, United States
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
Altimmune, Inc. · Alcohol Use Disorder (AUD)
Phase 2
Completed
100
2026-07
Altimmune, Inc. · Non-Alcoholic Steatohepatitis (NASH)
Phase 2
Completed
212
2026-05
Altimmune, Inc. · Alcohol Liver Disease
Phase 2
Recruiting
100
2026-03
Altimmune, Inc. · Obesity · Nonalcoholic Steatohepatitis
Phase 1
Completed
100
2025-06
Altimmune, Inc. · NASH - Nonalcoholic Steatohepatitis
Phase 1
Completed
40
2025-06
Altimmune, Inc. · Type 2 Diabetes
Phase 1
Completed
55
2025-06
Altor BioScience · Non-muscle Invasive Bladder Cancer
Phase 1 / Phase 2
Terminated
12
2024-07
Altor BioScience · Transitional Cell Carcinoma of Bladder · Urethra Cancer
Phase 1 / Phase 2
Completed
68
2024-06
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.